Jan omtalte også følgende på Jefferies - altså muligheder for øget Arzerra salg via andre stoffr i kombination med Arzerra:
-
Jan omtalte også følgende på Jefferies - altså muligheder for øget Arzerra salg via andre stoffr i kombination med Arzerra:
Det første er et snarligt opstart af fase III med GS-1101 (PI3K inhibitor) og Ofatumumab i pre-treated CLL patienter - her lidt beskrivelse:
Gilead commences GS-1101 Phase 3 trial in CLL
Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.
News-Medical (www.news-medical.net)
Herudover nævnte han kombination med en J&J PTk inhibitor.
Mvh
Sukkeralf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind